Markets:

Overview

News

Currencies

International

Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

182.55 +1.71 (+0.95%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Should You Buy Axsome Therapeutics Stock Before Feb. 23? ↗

February 05, 2026

The healthcare company is set to release its fourth-quarter results later this month.

Via The Motley Fool

1 High-Flying Stock With More Upside Ahead ↗

February 03, 2026

Are we witnessing the birth of a biotech giant?

Via The Motley Fool

Topics Intellectual Property

The Great Rotation: Russell 2000’s Historic 15-Day Streak Marks a Seismic Shift in Market Leadership

January 26, 2026

In a move that has rewritten the record books of Wall Street, the small-cap-heavy Russell 2000 index recently concluded a historic 15-session winning streak of daily outperformance against the S&P 500....

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

AXSOME THERAPEUTICS INC (NASDAQ:AXSM) Fits the Minervini Growth Momentum Strategy ↗

January 12, 2026

Via Chartmill

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

Where Axsome Therapeutics Stands With Analysts ↗

August 04, 2025

Via Benzinga

Earnings Scheduled For August 4, 2025 ↗

August 04, 2025

Via Benzinga

A Look at Axsome Therapeutics's Upcoming Earnings Report ↗

August 01, 2025

Via Benzinga

AXSM Stock Rises After Analyst Hikes Price Target On Auvelity Drug Optimism ↗

January 16, 2026

Piper Sandler kept an ‘Overweight’ rating on Axsome Therapeutics’ shares, and raised the price target to $223 from $148.

Via Stocktwits

Topics Artificial Intelligence

Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out ↗

January 08, 2026

Via MarketBeat

2 Healthcare Stocks to Buy for 2026 and Beyond ↗

January 08, 2026

These could be the next biotech giants.

Via The Motley Fool

Regencell Bioscience (RGC) Stumbles into 2026: 8% Year-End Slide Sparks Technical Caution

January 01, 2026

As the final bells rang on the 2025 trading year, investors in Regencell Bioscience (NASDAQ: RGC) were met with a sobering reality check. The Hong Kong-based biotech firm, which has enjoyed a meteoric...

Via MarketMinute

Here are the top movers in Wednesday's session. ↗

December 31, 2025

Via Chartmill

Why Axsome Therapeutics Stock Rocketed Higher to End 2025 ↗

December 31, 2025

Axsome Therapeutics shareholders got a New Year's gift from the FDA.

Via The Motley Fool

The market is filled with gapping stocks in Wednesday's session. ↗

December 31, 2025

Via Chartmill

Axsome Advances Toward FDA Filing For Drug To Treat Narcolepsy ↗

December 31, 2025

AXS-12 is being developed to treat cataplexy in narcolepsy by targeting norepinephrine and dopamine activity in the brain.

Via Stocktwits

Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth

December 11, 2025

As 2025 draws to a close, a powerful undercurrent of technological innovation, extending far beyond the pervasive influence of artificial intelligence, is demonstrably reshaping the global stock...

Via MarketMinute

Topics Artificial Intelligence Economy Emissions

2 Under-the-Radar Stocks to Buy Heading Into 2026 ↗

December 01, 2025

These drugmakers are poised to profit from their innovative engines.

Via The Motley Fool

Axsome (AXSM) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Axsome (AXSM) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

2 Monster Stocks in the Making ↗

November 10, 2025

There might still be time to get in on the ground floor.

Via The Motley Fool

Axsome Therapeutics Inc (NASDAQ:AXSM) Q3 2025 Earnings: Revenue Beat Overshadowed by Wider-Than-Expected Loss ↗

November 03, 2025

Axsome Therapeutics Q3 2025 results: Revenue beat expectations with strong product sales, but the company reported a wider-than-expected loss.

Via Chartmill

Uncovering Potential: Axsome Therapeutics's Earnings Preview ↗

October 31, 2025

Via Benzinga

Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years ↗

September 30, 2025

Both should have significant catalysts by the end of the decade.

Via The Motley Fool

Pharma Tariffs Back In Spotlight On New Trump Threat ↗

September 26, 2025

President Donald Trump threatened 100% tariffs on some drug imports.

Via Investor's Business Daily

Topics ETFs Government World Trade

Prediction: These 2 Biotech Stocks Could Double in the Next 5 Years ↗

September 04, 2025

Both companies have made significant progress in recent years.

Via The Motley Fool

A Glimpse Into The Expert Outlook On Axsome Therapeutics Through 8 Analysts ↗

September 03, 2025

Via Benzinga

Tonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 Years ↗

August 18, 2025

FDA approves Tonmya, a non-opioid fibromyalgia therapy from Tonix, with strong trial data and U.S. launch expected in late 2025.

Via Benzinga

Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings ↗

August 05, 2025

Via Benzinga

Axsome Therapeutics Inc (NASDAQ:AXSM) Reports Q2 2025 Revenue Beat and Narrower EPS Loss, Shares Surge 6% in Pre-Market Trading ↗

August 04, 2025

Axsome Therapeutics beats Q2 2025 revenue estimates with $150M, driven by Auvelity's 84% YoY growth. Shares rise 6% pre-market on improved EPS.

Via Chartmill

Axsome (AXSM) Q2 Revenue Soars 72% ↗

August 04, 2025

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.